Incyte Highlights the P-III (inMIND) Study Data of Monjuvi (Tafasitamab) to Treat R/R Follicular Lymphoma at ASH 2024
Shots:
- The P-III (inMIND) trial assessed Monjuvi & lenalidomide as an add-on to rituximab vs matching PBO to treat patients (n=654; ≥18yrs.) with r/r FL (Grade 1-3a) and nodal, splenic or extranodal MZL
- Study achieved its 1EP, showing improved PFS with mPFS of 22.4 vs 13.9mos. and a 57% reduction in the disease progression or death risk (by investigator evaluation). IRC evaluation depicted consistent PFS, with mPFS not reached vs 16mos.
- Trial also met 2EPs, showing CR of 9.4% vs 39.8%, ORR of 83.5% vs 72.4%, DoR of 21.2mos. vs 13.6mos. & median time to next treatment (TTNT) not reached vs 28.8mos. mOS was not achieved, though a positive trend was identified
Ref: Incyte | Image: Incyte
Related News:- Incyte and Syndax Receives US FDA Approval for Niktimvo (axatilimab-csfr) to Treat Chronic Graft-Versus-Host Disease (GvHD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
